Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) has announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of its Supervisory Board at the upcoming Annual General Meeting (AGM) scheduled for June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board and a proposal to expand the board from six to seven members.
Following constructive discussions, Evotec has entered into a cooperation agreement with MAK Capital Fund LP, a key shareholder. Under the terms of the agreement, MAK Capital has agreed to customary voting and cooperation commitments. This move reflects Evotec's commitment to open shareholder dialogue and long-term value creation.
Prof. Dr. Iris Low-Friedrich, Chairwoman of Evotec's Supervisory Board, stated: "We are pleased to nominate Wolfgang for election at the upcoming AGM. His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise, complementing our existing Board structure as we continue to implement our transformation plans to grow shareholder value. The agreement reached reflects Evotec’s commitment to constructive shareholder engagement, supporting the long‑term success of the Company."
Michael A. Kaufman, Chief Executive Officer of MAK Capital, added: "We appreciate the constructive dialogue and welcome Wolfgang’s nomination to the Supervisory Board. We look forward to continuing our collaboration with the Supervisory Board and Management Board to support Evotec's ongoing transformation."
Dr. Wolfgang Hofmann brings extensive industry, scientific, and governance expertise, which will strengthen Evotec's oversight capabilities as it executes its transformation plans. The cooperation agreement with MAK Capital underscores Evotec's dedication to shareholder engagement and alignment with key investors.
Evotec is a life science company pioneering drug discovery and development through AI-driven innovation and advanced technologies. The company works with all top 20 pharma companies, over 800 biotechs, and academic institutions. Its platform spans small molecules, biologics, cell therapies, and proprietary platforms such as Molecular Patient Databases, PanOmics, and iPSC-based disease modeling. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S.
The nomination and agreement signal a strategic effort to enhance board governance and secure shareholder support for Evotec's transformation initiatives. For leaders in business and technology, this development highlights the importance of board composition and shareholder relations in driving corporate change. The expansion of the Supervisory Board and addition of independent expertise could influence Evotec's strategic direction and operational focus, particularly in its AI-driven drug discovery efforts.
More information about Evotec is available at www.evotec.com. The original release can be viewed on www.newmediawire.com.
